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Abstract
Hemiplegic migraine (HM) is a rare and severe subtype of autosomal dominant
migraine, characterized by a complex aura including some degree of motor
weakness. Mutations in four genes (CACNA1A, ATP1A2, SCN1A and PRRT2)
have been detected in familial and in sporadic cases. This genetically and clini-
cally heterogeneous disorder is often accompanied by permanent ataxia, epilep-
tic seizures, mental retardation, and chronic progressive cerebellar atrophy.
Here we report a mutation screening in the CACNA1A and ATP1A2 genes in
18 patients with HM. Furthermore, intragenic copy number variant (CNV)
analysis was performed in CACNA1A using quantitative approaches. We identi-
fied four previously described missense CACNA1A mutations (p.Ser218Leu,
p.Thr501Met, p.Arg583Gln, and p.Thr666Met) and two missense changes in the
ATP1A2 gene, the previously described p.Ala606Thr and the novel variant
p.Glu825Lys. No structural variants were found. This genetic screening allowed
the identification of more than 30% of the disease alleles, all present in a het-
erozygous state. Functional consequences of the CACNA1A-p.Thr501Met muta-
tion, previously described only in association with episodic ataxia, and
ATP1A2-p.Glu825Lys, were investigated by means of electrophysiological stud-
ies, cell viability assays or Western blot analysis. Our data suggest that both
these variants are disease-causing.
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Introduction
Familial or sporadic hemiplegic migraine (FHM, MIM
#141599, or SHM) are rare subtypes of migraine with aura
(MA) characterized by paroxysmal episodes of hemiparesis
generally preceding or accompanying a headache attack
(International Headache Society [IHS] 2004)). FHM is
considered a monogenic disorder and follows an autoso-
mal dominant inheritance pattern (Pietrobon 2007). Both
FHM and SHM are genetically heterogeneous disorders.
Up to now, four causative genes have been described in
hemiplegic migraine (HM): CACNA1A on chromosome
19p13 (FHM1, MIM #301011) (Ophoff et al. 1996),
ATP1A2 at 1q23 (FHM2, MIM #182340) (De Fusco et al.
2003), SCN1A at 2q24 (FHM3, MIM #182389) (Dichgans
et al. 2005) and, recently, PRRT2 at 16p11.2 (MIM
#614386) (Riant et al. 2012). Additionally, two other loci
have been reported in FHM families at 1q31 (Gardner
et al. 1997) and 14q32 (Cuenca-Leon et al. 2009), although
the specific genetic defects have not yet been uncovered.
Mutational screenings of HM patients have reported
more than 30 mutations in the CACNA1A gene, over 60
mutations in the ATP1A2 gene, only five in SCN1A (de
Vries et al. 2009; Riant et al. 2010a; Freilinger et al. 2011)
and eight in PRRT2 (Cloarec et al. 2012; Dale et al. 2012;
Gardiner et al. 2012; Marini et al. 2012; Riant et al. 2012).
Additionally, a quantitative study that used multiple liga-
tion-dependent probe amplification (MLPA) identified a
deletion of exons 39–47 of CACNA1A in a SHM patient
(Labrum et al. 2009). CACNA1A encodes the pore-forming
a1 subunit of the voltage-gated neuronal Cav2.1 (P/Q-type)
channel. Cav2.1 channels are located in cortical glutamater-
gic presynaptic terminals and play an important role in con-
trolling neurotransmitter release. ATP1A2 encodes the a2
subunit of the Na+/K+ ATPase, is expressed in astrocytes
and is involved in the clearance of extracellular K+ and pro-
duction of a Na+ gradient used in the reuptake of glutamate.
SCN1A encodes the a1 subunit of the neuronal voltage-
gated sodium channel Nav1.1. This channel is critical in the
generation and propagation of action potentials (Wessman
et al. 2007). Finally, PRRT2 codes for a transmembrane pro-
tein of unknown function that is capable to bind to synapto-
somal-associated protein 25 (SNAP25), which suggests a
role in synaptic exocytosis (Lee et al. 2012).
The allelic heterogeneity displayed by the CACNA1A
gene also correlates with substantial clinical variation, as
mutations in this gene are also responsible for two other
autosomal dominant diseases: episodic ataxia type 2 (EA2,
MIM #108500) and spinocerebellar ataxia type 6 (SCA6,
MIM #183086). The range of CACNA1A-linked phenotypes
has even been broadened by the recent descriptions of
patients presenting with alternating hemiplegia of child-
hood (de Vries et al. 2008), acute striatal necrosis (Carre~no
et al. 2011), hemiplegia–hemiconvulsion–epilepsy syn-
drome (Yamazaki et al. 2011), and recurrent ischemic
stroke (Knierim et al. 2011). Clinical variation is also seen
within the HM phenotype, a condition in which CACNA1A
may sometimes be implicated as a modifier gene rather than
a disease-causing gene (Serra et al. 2010). Typical attacks in
HM are often associated with other aura symptoms: the
clinical spectrum includes permanent cerebellar signs and,
less frequently, various types of epileptic seizures, mental
retardation, and coma. Furthermore, in approximately 50%
of FHM1/CACNA1A families, chronic progressive ataxia
occurs independently of the migraine attacks (IHS 2004).
ATP1A2 has also been associated with alternating hemiple-
gia of childhood (Bassi et al. 2004). Also, the SCN1A gene
has been associated with phenotypes other than HM, as it
has been identified as a cause of generalized epilepsy with
febrile seizures plus type 2 (GEFS+2, MIM #604403)
(Escayg et al. 2000), severe myoclonic epilepsy in infancy
(SMEI, MIM #607208), also called Dravet syndrome
(Dravet 2011), childhood epilepsy with generalized tonic-
clonic seizures (ICEGTC, MIM #607208), familial febrile
convulsions type 3A (FEB3A, MIM #604403) (Mantegazza
et al. 2005), and elicited repetitive daily blindness (ERDB)
with HM (Vahedi et al. 2009). Finally, mutations in PRRT2
have been found in a number of paroxysmal disorders,
including paroxysmal kinesigenic dyskinesia (PKD,
MIM #128200), infantile convulsions with PKD (PKD/IC,
MIM #602066), benign familial infantile epilepsy
(BFIE, MIM #605751), and episodic ataxia or febrile sei-
zures, apart from HM (Wood 2012).
At the functional level, HM and EA2 mutations typi-
cally have opposite effects on the CaV2.1 channels leading
to increased or decreased Ca2+ influx, respectively (Pietro-
bon 2013). HM-related mutations in the ATP1A2 gene
typically produce a loss of function of the pump (de Vries
et al. 2009).
In a previous study, we analyzed 21 Spanish patients
with HM episodes and identified three mutations in the
CACNA1A gene, but no disease-causing changes in
ATP1A2 (Cuenca-Leon et al. 2008). In this study we ana-
lyzed 18 additional patients with HM of Spanish and
Greek origin and identified four mutations in the
CACNA1A gene and two mutations in ATP1A2. The two
changes that had not previously been studied at the func-
tional level were subjected to functional analyses to estab-
lish their relevance to the disease phenotype.
Materials and Methods
Patients
All 18 patients, examined and diagnosed by specialized
neurologists, fulfilled the International Criteria for
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Headache Disorders 2nd edition (IHS 2004) for FHM or
SHM diagnoses except patient #157, with probable HM
but only one severe HM episode at the time of diagnosis.
Clinical characteristics of the sample are presented in
Table 1 and the pedigrees in which mutations were iden-
tified are shown in Figure 1. One hundred Caucasian
Spanish or Greek unrelated adult control individuals with
no personal or family history of recurrent or disabling
headache were screened for the presence of the changes
identified in the CACNA1A and ATP1A2 genes. The
Spanish controls were blood donors or individuals that
underwent surgery unrelated to migraine at Hospital Vall
d’Hebron (Barcelona), whereas the Greek ones were
healthy individuals collected as controls for a mutation
screening of cystic fibrosis. This study was approved by
the local Ethics Committee and informed consent was
obtained from all adult subjects, children, and their par-
ents according to the Helsinki declaration.
Sampling and mutation screening
Peripheral blood samples were collected from all pro-
bands. Genomic DNA was isolated using a standard salt-
ing-out method (Miller et al. 1988). The CACNA1A and
ATP1A2 genes were sequenced as previously described,
including all exons, splice sites, and branch points (Cu-
enca-Leon et al. 2008).
The promoter and 3′UTR regions of CACNA1A were
also included in the mutational screening. We covered an
894-bp region upstream from the initiation codon and a
553-bp segment including exon 48, as previously
described (Veneziano et al. 2009). The extension of the
mutational screening was also applied to 18 HM patients
from our previous study (Cuenca-Leon et al. 2008). All
mutations were assessed by bidirectional sequencing. In
addition, all mutations were confirmed by restriction
fragment length polymorphism (RFLP) analysis of poly-
merase chain reaction (PCR) products (Table 2). Control
individuals were screened by Sanger sequencing, single-
strand conformation polymorphism or RFLP analysis to
test the possible presence of the identified changes. Muta-
tion nomenclature follows HGVS guidelines (http://www.
hgvs.org/mutnomen/recs-DNA.html) and refers to the
CACNA1A cDNA sequence NM_023035.1 (protein
sequence NP_075461.2), with nucleotide 283A (ATG) cor-
responding to +1 and the ATP1A2 cDNA sequence
NM_000702.3 (protein sequence NP_000693.1) with nucle-
otide 1A (ATG) corresponding to the initiation codon.
Copy number variant (CNV) analysis of CACNA1A was
performed using two complementary approaches in order
to cover most exons (Fig. S1): MLPA and quantitative
multiplex PCR of short fluorescent fragments (QMPSF).
For the MLPA assay, we used the SALSA MLPA kit P279-
A2 for CACNA1A (MRC-Holland, Amsterdam, the Neth-
erlands), and for QMPSF we used four sets of probes that
covered 16 additional exons not included in the MLPA
kit design. Further information about the methods and
analysis is provided in Figure S1 and PCR conditions and
sample analysis are available upon request.
Paternity was assessed in the de novo mutation identi-
fied as previously described (Carre~no et al. 2011).
DNA constructs and site-directed
mutagenesis
Human a1A (CaV2.1) was originally cloned into a pCMV
vector and mutation p.Thr501Met was introduced by site-
directed mutagenesis (GenScript Corporation, Piscatway,
NJ). Rabbit a2d and rat CaVb3 CaV2.1 channel regulatory
subunits were subcloned into a pcDNA3 expression vector.
A full-length human ATP1A2 ouabain-resistant cDNA
clone (a2_oua_wt, with p.Gln116Arg and p.Asn127Asp
changes conferring ouabain resistance), housed in
pcDNA3.1 with themyc tag, was used. Mutation c.2473G>A
(a2_oua_825Lys) was introduced in a a2_oua_wt clone with
the QuickChange II XL Site-Directed Mutagenesis Kit
(Stratagene, La Jolla, CA).
All cDNA clones used in this study were sequenced in
full to confirm their integrity.
Functional analysis of CACNA1A
Heterologous expression and electrophysiology
HEK 293 cells were transfected using a linear polyethyle-
neimine (PEI) derivative, the polycation ExGen500 (Fer-
mentas Inc., Hanover, MD) (8 equivalents PEI/3.3 lg
DNA/dish) as previously reported (Fernandez-Fernandez
et al. 2004). Transfection was performed using the ratio
for a1A (wild type or p.Thr501Met), CaVb3, a2d, and
EGFP (transfection marker) of 1:1:1:0.3. Recordings were
done 24–72 h after transfection.
Calcium currents (ICa) through wild-type (WT) or
p.Thr501Met CaV2.1 (P/Q) channels were measured using
the whole-cell configuration of the patch-clamp technique
(Hamill et al. 1981). Pipettes had a resistance of 2–3 MΩ
when filled with a solution containing (in mmol/L): 140
CsCl, 1 EGTA, 4 Na2ATP, 0.1 Na3GTP, and 10 Hepes
(pH 7.2–7.3 and 295–300 mosmoles/L). The external
solution contained (in mmol/L): 140 tetraethylammoni-
um-Cl, 3 CsCl, 2.5 CaCl2, 1.2 MgCl2, 10 Hepes, and 10
glucose (pH 7.3–7.4 and 300–305 mosmoles/L). Record-
ings were obtained with a D-6100 Darmstadt amplifier
(List Medical, Germany), filtered at 1 kHz and corrected
for leak and capacitive currents using the leak subtraction
procedure (P/8). Currents were acquired at 33 kHz. The
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pClamp8 software (Axon Instruments, Foster City, CA)
was used for pulse generation, data acquisition, and sub-
sequent analysis.
Peak inward Ca2+ currents were measured from cells
clamped at 80 mV and pulsed for 20 msec from 60 mV
to +70 mV in 5 mV steps. A modified Boltzmann equation
(eq. 1) was fitted to normalized current voltage (I–V) to
obtain the voltage dependence of activation. The voltage
dependence of steady-state inactivation was estimated by
measuring peak ICa currents at +20 mV following 30-sec
steps to various holding potentials (conditioning pulses)
between 80 and +5 mV. During the time interval between
Table 1. Clinical features of 18 patients with HM and other accompanying symptoms.
Patient Gender
Age
(years)
Age at
onset
(years)
Triggering
factors Diagnosis
Other
ictal
features Other
Family
history Origin Mutation
5C F 50 11–12 – FHM – – MA, HM Spain –
A03_44 F 66 – – FHM – Nystagmus,
progressive
ataxia
HM Spain p.Thr501Met
(CACNA1A)
A00_100 F 31 Adolescent – FHM Episodic
ataxia
Progressive
ataxia,
cerebellar
atrophy on
MRI
HM, MA,
EA2
Spain p.Arg583Gln
(CACNA1A)
99 F 40 8 Fasting SHM MA – MO Spain –
112 M 19 11–12 – SHM MO – Headache Spain –
157 M 15 8 Stress HM (1
episode)
MA – MA, MO,
vestibular
migraine
Spain –
161 M 20 11 – SHM – – Spain –
322B F 47 <10 – FHM MA Interictal
cerebellar
signs
HM,
interictal
nystagmus
Spain p.Thr666Met
(CACNA1A)
388A F 15 11 – FHM – – HM Spain –
391A F 11 5 Stress SHM Generalized
seizure,
transient
cerebral
edema on
MRI
– MO Greece p.Ser218Leu
(CACNA1A,
de novo)
431 F 42 38 Stress SHM – – MO Spain –
475 F 50 14 – FHM – – HM Spain –
I713 M 37 12 – FHM MA – HM, MA Spain –
G248 F 43 17 Stress,
menses
SHM Aphasia – – Spain –
8873 F 37 9 – FHM Aphasia,
transient
episodes of
bilateral
visual loss
– HM Spain –
I310 F 47 15 Stress,
strong
odors
FHM Partial
epileptic
seizures
– HM Spain p.Ala606Thr
(ATP1A2)
387A M 10 2 Head
injury
FHM Febrile
seizures
Tension-type
headache
HM Greece p.Glu825Lys
(ATP1A2)
489A F 8 5 – FHM Prolonged
dysphasia/
confusion
Nystagmus,
cerebellar
atrophy on
MRI
MA, panic
attacks
Spain –
HM, hemiplegic migraine; FHM, familiar hemiplegic migraine; SHM, sporadic hemiplegic migraine; MA, migraine with aura; MO, migraine without
aura; EA2, episodic ataxia type 2; MRI, magnetic resonance imaging.
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test pulses (20 msec) cells were held at 80 mV. ICa cur-
rents obtained following the conditioning pulses were nor-
malized to maximal ICa to determine the persistent current.
Half-maximal voltage (V1/2, inact) was obtained by fitting
the data to the following Boltzmann equation (eq. 2). All
experiments were carried out at room temperature (22–
24°C).
I ¼ GmaxðV  VrevÞ=ð1þ expð½V  V1=2;act=kactÞÞ (1)
I=Imax ¼ 1=ð1þ expð½V  V1=2;inact=kinactÞÞ (2)
A
B
Figure 1. Pedigrees of patients with the identified gene variants. (A) Mutations in the CACNA1A gene. (B) Mutations in the ATP1A2 gene.
Affected individuals are denoted by solid symbols; hemiplegic migraine (HM) in black and other phenotypes in gray; squares indicate males and
circles females. Probands are indicated by a black arrow. Clinical characteristics are indicated below each individual (HM, migraine with
hemiplegic aura; MA, migraine with aura; CA, cerebellar atrophy; EA2, episodic ataxia type 2). Gene variant carrier status is indicated below each
patient when known. Mutation p.Ser218Leu appeared de novo in the affected sib.
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Statistics
Data are presented as the means  SEM. Student’s t test
or Mann–Whitney test was used for statistical analysis, as
appropriate. The t test assumes that data are sampled
from population that follow a normal distribution and
with equal standard deviations. Therefore, the use of the
Mann–Whitney test is justified either if at least one of the
two population data that are compared fails the normality
test (using the Kolmogorov–Smirnov method) or if there
are significant differences among the standard deviations
of the two populations. Differences were considered sig-
nificant if P < 0.05.
Functional analysis of ATP1A2
Cell viability assay
HeLa cells were transfected with 2 lg of constructs using
Lipofectamine 2000 (Invitrogen, Carlsbad, CA). Forty-
eight hours after transfection, 2/3 of the cells were har-
vested for Western blot analysis and 1/3 of cells were
seeded in petri dishes. After 24 h, the Na+/K+-ATPase
inhibitor ouabain (1 lmol/L) was added to the medium
(Dulbecco’s modified eagle medium containing 10% fetal
calf serum and 1% Penicillin-Streptomycin). After 48 h of
ouabain exposition, cell viability was quantified with the
3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bro-
mide (MTT) reduction assay (De Fusco et al. 2003; Van-
molkot et al. 2003).
Western blot analysis
A volume of 25 lg of total protein extract (per lane) was
subjected to 10% sodium dodecyl sulfate-polyacrylamide
gel electrophoresis. Gels were transblotted to a nitrocellu-
lose membrane and were incubated overnight with
monoclonal antibodies against c-Myc (4 lg/mL). Horse-
radish peroxidase-conjugated anti-mouse immunoglobu-
lins were used as a secondary antibody. Proteins were
visualized with the enhanced chemiluminescence kit (GE
Healthcare, Little Chalfont, Buckinghamshire, U.K.). Blots
were probed with antitubulin antibodies as a loading
control.
Statistics
We performed four independent experiments, each with
triplicate measurements, and carried out statistical analy-
ses by the Student’s t test, considering one-tail distribu-
tion and two-sample equal variance (homoscedastic).
Statistical significance was set at P < 0.05.
Results
Clinical data
Eighteen patients with HM and other accompanying clini-
cal features were identified and screened for mutations in
the CACNA1A and ATP1A2 genes. Eleven were classified
Table 2. Disease-causing mutations identified in the CACNA1A and ATP1A2 genes in hemiplegic migraine patients.
Patient Gene
Mutation position
Detection method Phenotype
Previously
reported in
other patients ReferenceProtein cDNA Exon Protein domain
391A CACNA1A p.Ser218Leu c.653C>T 5 Cytoplasmic,
IS4-5
TaqI SHM and
generalized
seizures
HM Kors et al.
(2001, #164)
A03_44 CACNA1A p.Thr501Met c.1502C>T 11 Transmembrane,
S1 DII
+FatI FHM,
progressive
ataxia
EA2 Mantuano et al.
(2010, #165)
A00_100 CACNA1A p.Arg583Gln c.1748G>A 13 Transmembrane,
S4 DII
BanII FHM, EA2,
progressive
ataxia
HM Ducros et al.
(2001, #166)
322B CACNA1A p.Thr666Met c.1997C>T 17 Transmembrane,
hairpin loop DII
+BccI FHM, MA HM Ophoff et al.
(1996, #119)
387A ATP1A2 p.Glu825Lys c.2473G>A 18 Cytoplasmic loop,
L6/7
PvuII FHM No –
I310 ATP1A2 p.Ala606Thr c.1816G>A 13 Cytoplasmic loop,
M4/5
+HhaI FHM, partial
epileptic
seizures
HM Riant et al.
(2005, #922)
HM, hemiplegic migraine; FHM, familiar hemiplegic migraine; SHM, sporadic hemiplegic migraine; MA, migraine with aura; EA2, episodic ataxia
type 2.
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as FHM and seven as SHM. The clinical characteristics of
all patients are summarized in Table 1.
As previously described, we observed a preponderance
of female patients in our HM population (13 female
patients/five male patients). Age of onset was known for
17 cases. Seven patients presented onset within the first
decade; the youngest age of presentation of hemiplegia
was at age 2 in one FHM case (#387A). Onset in post-
puberty or adolescence was documented in nine patients
while in one case (#431) an unusual late onset in the
fourth decade was reported. The episodes triggering fac-
tors did not differ from those commonly associated
with common migraine, except for mild head trauma-
induced attacks in case #387A, bearing an ATP1A2
mutation.
Other ictal manifestations were common in this cohort
of HM patients: four cases developed migraine with typi-
cal visual or sensory aura and one migraine without aura
(MO) episodes; three had episodes of aphasia or dyspha-
sia, presumably the expression of migrainous aura, in the
absence of concurrent hemiplegia. Two patients developed
epileptic seizures, one partial and one generalized, and
one patient had a history of febrile seizures; transient
visual loss and episodic ataxia were described in one case
each.
Four patients had interictal, permanent neurological
abnormalities, mainly a cerebellar syndrome featuring
nystagmus and different degrees of chronic ataxia. Three
or these harbored mutations in one of the two analyzed
genes. All patients were subjected to MRI studies. The
only remarkable neuroradiologic findings were chronic
cerebellar atrophy in three cases and cerebral edema at
the time of the episodes in one case. The remaining
patients did not have any chronic disability and had nor-
mal interictal exams (Table 1).
A more detailed clinical description of patient #387A
and his father, bearing a previously undescribed mutation
in the ATP1A2 gene, is provided as supplementary mate-
rial (see Data S1).
Genetic analysis
The extensive sequencing of the CACNA1A gene in 18
subjects with HM allowed the identification of four pre-
viously reported changes in four unrelated families. In
the remaining 14 patients, a novel and a previously
described mutation was detected in the ATP1A2 gene
(Table 2 and Fig. 2). The presence of all these variants
was confirmed by restriction analysis of the correspond-
ing PCR products (Table 2). The identified changes were
not present in 100 Spanish nonmigraineurs. The novel
p.Glu825Lys mutation in the ATP1A2 gene, identified in
a Greek patient, was also absent from a set of 100
healthy Greek individuals. One of the changes, p.Ser218-
Leu, was present in the affected sib, but not in her par-
ents, indicating a de novo origin (Fig. 1A). False
paternity was excluded by genotyping 16 polymorphic
microsatellite markers in all the family members (data
not shown).
All the identified mutations led to amino acid substitu-
tions (p.Ser218Leu, p.Thr501Met, p.Arg583Gln, and
p.Thr666Met in CACNA1A; p.Glu825Lys and p.Ala606Thr
in ATP1A2). One of them, p.Glu825Lys in ATP1A2, is
described here for the first time. The rest of the changes
had previously been reported in other patients from sev-
eral countries, four of them in HM and only one,
p.Thr501Met in CACNA1A, in association with another
phenotype, EA2.
The CACNA1A-p.Thr501Met mutation, described only
once prior to this study, and the novel missense mutation
p.Glu825Lys in ATP1A2, both of them subjected to func-
tional studies in this study (see below), alter amino acid
residues that are highly conserved in evolution as shown
by a comparison of their paralogous and orthologous
counterparts (Fig. 3). The p.Glu825Lys variant segregates
with the HM phenotype, being transmitted from the
affected father to the affected sib (Fig. 1B; for a detailed
clinical description see Data S1). DNA was not available
from the p.Thr501Met family, where a son and a daugh-
ter of the studied proband (#A03_44) have also been
diagnosed with HM.
The 12 patients with no mutations identified after
extensive CACNA1A and ATP1A2 sequencing, as well as
18 HM patients negative for a mutational screening per-
formed in our previous study (Cuenca-Leon et al. 2008),
were subjected to MLPA/QMPSF quantitative analysis to
seek duplications/deletions in the CACNA1A gene. How-
ever, no structural variations were found in these pro-
bands.
Functional studies
We subjected two of the identified mutations, p.Thr501Met
(CACNA1A) and p.Glu825Lys (ATP1A2), to functional
analyses. These changes are the only ones that had not pre-
viously been studied by other authors at the functional
level.
CACNA1A (p.Thr501Met): current density and
activation/inactivation voltage dependence of
heterologously expressed CaV2.1 (P/Q) channels
Mutation p.Thr501Met changes a hydrophilic amino acid
to a hydrophobic one and is located in a functionally
important region of the human a1A subunit of the neuro-
nal CaV2.1 (P/Q-type) Ca
2+ channel (Fig. 2A). It lies in
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AB
Figure 2. Gene structure of CACNA1A and ATP1A2 and detection of mutations. (A) 1: CACNA1A gene structure, with black boxes indicating
exons. The identified mutations causing HM are indicated by colored dots: p.Ser218Leu (light green), p.Thr501Met (red), p.Arg583Gln (blue), and
p.Thr666Met (purple). 2: Protein structure and location of the identified mutations. (B) 1: ATP1A2 gene structure, with black boxes indicating
exons. The newly identified mutation p.Glu825Lys causing HM is indicated by a yellow dot and p.Ala606Thr with a green dot. 2: Protein structure
and location of the identified mutations. Detection of the mutations by direct sequencing of PCR products: electropherograms. Cyt, cytoplasm;
M, cytoplasmic membrane; ES, extracellular space.
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the S1 segment of domain II (II-S1) (Fig. 2A), which
makes up part of the voltage sensor (Tombola et al.
2006). Because in a previous study of a patient with HM
we found that another S1 mutation, p.Tyr1245Cys in
domain III of the protein mainly affected voltage depen-
dence of both activation and inactivation of the channel
(Serra et al. 2009), we focused our functional analysis of
the p.Thr501Met mutation on those same parameters.
Maximum current densities resulting from expression
of mutant p.Thr501Met a1A (a1A(T501M)) were signifi-
cantly higher than current densities of wild-type (WT)
a1A channels (P < 0.05) in a physiological range of depo-
larized voltages (from 15 to +5 mV) (Fig. 4A and B,
left panel). The potential for half-maximal activation
(V1/2, act) was also significantly (P < 0.0001) shifted to
hyperpolarized potentials for p.Thr501Met channels (by
~7 mV) (Fig. 4B, right panel). Consistently, the maxi-
mum current amplitude was elicited by depolarizing
pulses to ~ +15 mV or ~ +5 to +10 mV for WT or
p.Thr501Met channels, respectively (Fig. 4A and B).
The half-maximal voltage for steady-state inactivation
(V1/2, inact) induced by 30-sec-conditioning prepulses
between 80 and +5 mV was left-shifted (~12 mV) in
p.Thr501Met channels (P < 0.0001). (Fig. 4C and D).
ATP1A2 (p.Glu825Lys): Ouabain resistance survival
assays
p.Glu825Lys exchanges a negatively charged residue for a
positive one and is located in the intracellular L6/7 loop
of the ATP1A2 protein, between the transmembrane seg-
ments M6 and M7 (Fig. 2B). Potential pathogenicity of
the mutation p.Glu825Lys was indirectly tested through
ouabain resistance survival assays.
HeLa cells transfected with the a2_oua_825Lys con-
struction showed a 10% survival rate, compared with cells
transfected with a2_oua_ WT (P < 0.0003) (Fig. 5A).
Western blot analysis of HeLa extracts obtained after
transfection with the mutant and WT constructions
showed a diminished amount of 825Lys protein com-
pared with the WT, indicating that the altered protein
may be unstable (Fig. 5B).
Discussion
We have identified six potentially disease-causing mis-
sense mutations in the CACNA1A and ATP1A2 genes in a
cohort of 18 unrelated probands with HM from Spain
and Greece (33% of patients covered).
There is evidence supporting the finding that the iden-
tified amino acid substitutions are indeed disease-causing
mutations: (1) When family material was available, the
mutations cosegregated with the disease phenotype within
the families, (2) the changes were not present in at least
200 chromosomes from unaffected individuals nor in the
main public single-nucleotide polymorphism databases
(Hapmap, dbSNP), (3) no other molecular alterations
were identified within the studied genes after the analysis
of the whole coding region and the exon–intron bound-
aries, including splice sites, branch points, the promoter,
and the 3′UTR region in CACNA1A, (4) for the two
mutations subjected to functional studies the involved
amino acid residues are strongly conserved in evolution,
both at the intraspecific (CACNA1A, B, C, D, E, F, S or
ATP1A1, A2, A3, A4) and interspecific levels (CACNA1A
Figure 3. Protein alignment performed with ClustalW (http://www.
ebi.ac.uk/Tools/msa/clustalw2) (Chenna et al. 2003). On top, the
CACNA1A Thr501 residue is conserved in all the human calcium
channel a1 subunits studied (CACNA1A, B, C, D, E, F, and S) and in
the orthologous CACNA1A proteins of several organisms. Bottom, the
ATP1A2 Glu825 residue is conserved in the four human ATP1
paralogous subunits (ATP1A1, A2, A3, and A4) and in orthologous
ATP1A2 proteins of several organisms. Key: “*” identical residues; “:”
conserved substitutions (same amino acid group); “.” semi-conserved
substitution (similar shapes). Human: Homo sapiens; Bovin: Bos
taurus; Rat: Rattus norvegicus; Mouse: Mus musculus; Fish (Zebrafish):
Danio rerio.
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or ATP1A2 subunits from human, cattle, rat, mouse and
zebrafish), indicating functional/structural relevance, (5)
all these mutations but one (p.Glu825Lys) have been
reported previously in other HM or EA2 cohorts, and (6)
functional analyses reported here (p.Thr501Met in CAC-
NA1A and p.Glu825Lys in ATP1A2) and by other authors
(p.Ser218Leu [Tottene et al. 2005; Weiss et al. 2008;
Debiais et al. 2009; Adams et al. 2010], p.Arg583Gln
[Kraus et al. 2000] and p.Thr666Met [Kraus et al. 1998;
Tottene et al. 2002] in CACNA1A; p.Ala606Thr [Jen et al.
2007; Tavraz et al. 2008] in ATP1A2) demonstrate func-
tional consequences of all six changes suggesting pathoge-
nicity.
Interestingly, all but one of the patients that have HM
plus additional ictal/interictal neurological features or
atypical paroxysmal signs (e.g., epilepsy or cerebral edema
on MRI) bore mutations in one of the two genes studied.
In general, this was not the case for patients without such
“extended” HM phenotype, with no mutations identified
in those genes. The molecular defects associated with this
extended phenotype are unlikely to mimic those present
in common migraine. It is, however, possible that HM
cases without known mutation and with less severe clini-
cal presentations, which often overlap with common
migraine (in our series most had MO and MA attacks in
addition to HM) may represent a better model for pri-
mary headaches. In this regard, deciphering the molecular
basis of this group of patients may shed new light on the
global landscape of migraine genetics.
CACNA1A screening
Four patients presented missense mutations in the CAC-
NA1A gene, all of them described in previous screenings by
other authors: p.Ser218Leu, p.Arg583Gln, p.Thr666Met,
and p.Thr501Met (Fig. 2A).
p.Ser218Leu
This change was identified as a de novo mutation in a
SHM patient with aphasia, transient cerebral edema and
generalized seizures. This transition in a CpG dinucleotide
had been described in eight HM patients (Kors et al.
2001; Curtain et al. 2006; Chan et al. 2008; Debiais et al.
2009; Stam et al. 2009; Zangaladze et al. 2010) having
appeared de novo in two of them (Stam et al. 2009). Pre-
vious electrophysiological studies for the p.Ser218Leu
mutation revealed a lower activation threshold, an
increase of channel recovery after inactivation (Tottene
et al. 2005) and the reduction of the inhibitory pathway
carried by G-protein-coupled-receptor activation (Weiss
et al. 2008). This dramatic gain of function, compared to
A B
C D
Figure 4. Mutation p.Thr501Met affects activation and inactivation properties of heterologously expressed P/Q channels. (A) Current traces
illustrating voltage dependence of WT (left) and p.Thr501Met (right) P/Q channels, in response to 20 msec voltage pulses. Dotted lines in the
current traces indicate the zero current level. (B) Current density–voltage relationships (left panels) and normalized I–V curves (right panels) for WT
(○) and p.Thr501Met (●) P/Q channels expressed in HEK 293 cells. V1/2, act and kact values were (in mV): WT (○, n = 9) 7.1  0.8 and 3.3  0.3;
p.Thr501Met (●, n = 14) 0.04  0.99 and 2.8  0.3, respectively. No significant difference was found for kact values (P = 0.29). (C and D)
Steady-state inactivation of WT or p.Thr501Met P/Q channels. Amplitudes of currents elicited by test pulses to +20 mV were normalized to the
current obtained after a 30-sec prepulse to 80 mV and fitted by a single Boltzmann function (see Materials and Methods, eq. 2). V1/2, inact and
kinact values were (in mV): WT (○, n = 10) 24.2  0.9 and 5.5  0.4; p.Thr501Met (●, n = 15) 35.9  1 and 5  0.2, respectively. No
significant difference was found for kinact values (P = 0.53).
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other missense changes, is thought to explain the severe
clinical outcome observed in the patients carrying this
mutation. Studies with a mouse model provide evidence
that p.Ser218Leu mutations directly affect Ca2+-dependent
facilitation and synaptic plasticity (Adams et al. 2010).
p.Arg583Gln
This prevalent mutation has been previously identified in
FHM families and in sporadic patients (Battistini et al.
1999; Ducros et al. 2001; Terwindt et al. 2002;Alonso
et al. 2003; Thomsen et al. 2007; Riant et al. 2010a). In
family #A00_100, only the proband presents HM
(Fig. 1A) and the mutation cosegregates with EA2, cere-
bellar atrophy and/or HM. Previous functional studies for
the p.Arg583Gln mutation revealed a change in the volt-
age dependence of activation and inactivation toward
more negative potentials due to the neutralization of resi-
due 583 that is positively charged in the WT channel, and
a decrease in the recovery of inactivation (Kraus et al.
2000).
p.Thr666Met
This is also a prevalent mutation that has previously
been found in 24 FHM or SHM probands (Ophoff
et al. 1996; Ducros et al. 1999; Friend et al. 1999; Ter-
windt et al. 2002; Wada et al. 2002; Kors et al. 2003;
Thomsen et al. 2007; Freilinger et al. 2008; Yabe et al.
2008; Riant et al. 2010a) Functional studies in heterolo-
gous systems showed a gain of function through the
following mechanisms: a decrease in the recovery after
inactivation (Kraus et al. 1998) and increased Ca2+
influx through the channel in a broad voltage range
around the threshold of activation, which was also
reduced (Tottene et al. 2002).
p.Thr501Met
This change, found in patient #A03_044 with FHM, nys-
tagmus, and episodic and progressive ataxia, has been
described in another family with EA2 (Mantuano et al.
2010) and in a case with bouts of episodic ataxia and con-
fusion but no hemiplegia, in association with vermian cere-
bellar atrophy (Cleves et al. 2009). This is the second
reported mutation in the S1 segment in any domain of the
a1A subunit in patients with HM. As the previously
described p.Tyr1245Cys (Serra et al. 2009), p.Thr501Met
alters channel activation and inactivation. It promotes
channel activity by shifting the current activation curve to
lower voltages (~9 mV) and increasing Ca2+ current den-
sity to a range of voltages that neurons can encounter dur-
ing action potential firing. p.Thr501Met also shifts voltage-
dependent steady-state inactivation to less depolarized
voltages (~15 mV). These results further support an
important role of the S1 segments in the function of volt-
age sensors leading to channel gating (Campos et al. 2007).
The functional consequences of mutation p.Thr501Met
are consistent with a causative role in the disease. In this
respect, a reduction in the voltage threshold of channel
activation by ~10 mV is a trait shared by all FHM-caus-
ing mutations in CACNA1A (van den Maagdenberg et al.
2004; Tottene et al. 2005). Such gain of channel function
specifically promotes cortical excitatory neurotransmission
and favors cortical spreading depression (CSD) initiation
and propagation in FHM knock-in (KI) mouse models
(Tottene et al. 2009), which has been pointed out as the
cause of the aura and migraine itself (Bolay et al. 2002;
Pietrobon 2007).
Mutations in CACNA1A are also associated with other
autosomal dominant neurological disorders characterized
A
B
Figure 5. (A) Viability of HeLa cells transfected with the mutant
ATP1A2 cDNA (E825K) normalized to the viability of cells transfected
with the ouabain-resistant wild-type ATP1A2 cDNA (WT). NT,
untransfected cells; pcDNA3.1, cells transfected with the empty
vector. Four independent experiments were performed, each with
triplicate measurements. The * symbol indicates the existence of
significant differences between the p.Glu825Lys and the WT ATP1A2
constructs (P < 0.0003). (B) Western blot assay of the different
protein extracts using anti-myc and anti-tubulin antibodies. The
molecular weight of the Na+/K+-ATPase a2 subunit and tubulin are
indicated. The constructs with the ATP1A2 ouabain-resistant cDNA
carry the myc tag. The clone with the mutation displayed diminished
band intensity.
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by cerebellar dysfunction, such as EA2 (Ophoff et al.
1996). However, contrary to FHM mutations, most EA2
mutations produce loss-of-channel function (Strupp et al.
2007). Our patient carrying the p.Thr501Met CACNA1A
mutation also developed cerebellar symptoms. This also
occurred with other FHM-causing CACNA1A mutations
(Ducros et al. 2001). As yet, it is not clear why some
CACNA1A mutations cause pure FHM and other FHM
with cerebellar signs, as functional studies in vitro do not
reveal any notable difference among these two groups of
FHM mutations (Pietrobon 2007). Nevertheless, the study
of p.Arg192Gln and p.Ser218Leu KI animals may help us
to unveil the role of FHM CACNA1A mutations in EA2
(van den Maagdenberg et al. 2004, 2010). While homozy-
gous p.Arg192Gln (RQ/RQ) and heterozygous p.Ser218-
Leu (SL/WT) mice did not exhibit an overt phenotype,
homozygous p.Ser218Leu (SL/SL) KI model exhibited the
main features of the severe p.Ser218Leu clinical syn-
drome, including mild permanent cerebellar ataxia (van
den Maagdenberg et al. 2004, 2010).
ATP1A2 screening
p.Ala606Thr
This mutation was found in a patient with FHM and
focal epileptic seizures. It has previously been reported in
three FHM families (Jen et al. 2007; Riant et al. 2005).
Functional assays on HeLa cells transfected with WT and
mutant ATP1A2 constructs suggested a loss of function of
the sodium–potassium pump (Jen et al. 2007). Same
results were found for mutations p.N717K and p.P786L,
also located in the L4/5 cytoplasmatic loop of the protein
(Jen et al. 2007; Tavraz et al. 2008). A more detailed elec-
trophysiological functional study showed that the Na+/
K+-ATPase activity was decreased due to a lower affinity
for potassium (Tavraz et al. 2008).
p.Glu825Lys
This novel change, located in the L6/7 loop (Fig. 2B), was
identified in an individual with HM and seizures. Oua-
bain-resistant survival assays showed a decrease in cell
viability in HeLa cells transfected with the mutant
ATP1A2 construct (Fig. 5A), again supporting the idea
that the mutation results in loss of function of the
sodium–potassium pump. Also, Western blot analysis
suggests that the mutant protein may be unstable. Other
mutations in this loop that have been identified by others
and were functionally tested are as follows: p.Met829Arg,
p.Arg384*, and p.Arg834Gln (de Vries et al. 2007; Tavraz
et al. 2008). p.Arg834* showed no cell survival in ouabain
challenge assays, and electrophysiological analyses of
p.Arg834Gln displayed altered affinities for extracellular
cations or reduced enzyme turnover. It was suggested that
negatively charged residues in loop L6/7 contribute to the
initial recognition of Na+ or K+ ions and constitute the
cytoplasmic cation entry port (Shainskaya et al. 2000; Jor-
gensen et al. 2003). Other experiments found that loop
L6/7 is important in the transmission of the activation
signal initiated by cation binding to the phosphorylation
domain of the protein (Xu et al. 2003). These experi-
ments included a Glu to Ala mutation in a Ca2+-ATPase
that is equivalent to the p.Glu825Lys identified in our
patient.
Unidentified mutations/genes
Overall, 12 of 18 HM patients included in this study do
not bear mutations in either CACNA1A or ATP1A2. Con-
sidering also the HM patients screened by us in a previ-
ous study (Cuenca-Leon et al. 2008), the level of
molecular identification is 9/39 (23%), suggesting the
involvement of other genes that still need to be uncov-
ered. In sum, from these 39 patients, 22 were FHM (eight
bearing mutations, 36%) and 17 were SHM (only one
identified mutation, 6%). These data are in line with pre-
vious studies where the coverage was around 40% in
FHM patients (Riant et al. 2005) and between 7% and
16% in SHM (Terwindt et al. 2002; de Vries et al. 2007),
indicating that CACNA1A and ATP1A2 are major genes
in the familial forms of HM but not in the sporadic ones,
where there might be a larger genetic heterogeneity and/
or other contributing factors. Only in one study with
SHM patients presenting an early-onset of the disease the
coverage was higher when analyzing the CACNA1A,
ATP1A2, and SCN1A genes (Riant et al. 2010a). It is also
possible that a few pathogenic mutations have remained
unidentified in the two genes studied, including changes
in introns or in distant regulatory regions, or CNVs in
ATP1A2 that may be undetectable by PCR. Previously, a
large rearrangement in the CACNA1A gene was described
in a SHM patient (Labrum et al. 2009), and so it is con-
ceivable that deletions or duplications in ATP1A2 could
also be responsible for the disorder. However, CNV anal-
ysis has only reported this single deletion in CACNA1A
so far in HM, and this type of alteration is more fre-
quently found in episodic ataxia, where the typical patho-
genic mechanism is a loss of function of the channel
(Riant et al. 2008, 2010b; Labrum et al. 2009; Wan et al.
2011).
Mutations in SLC4A4 have been reported in pedigrees
with proximal renal tubular acidosis (pRTA) with HM
and migraine (Demirci et al. 2006; Suzuki et al. 2010),
but this gene was not considered in this study as none of
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the patients in our series showed renal abnormalities.
Mutations in the SCN1A gene, previously linked to FHM
and involved in several forms of epilepsy, would appear
to be a rather unusual cause of HM. Indeed, more than
700 mutations have been identified in SCN1A with SMEI
compared to just five in FHM (http://www.molgen.
vib-ua.be/SCN1AMutations) (Claes et al. 2009). Further-
more, very recently the genetic heterogeneity of HM phe-
notype has been broadened with the PRRT2 gene,
previously related to paroxysmal kinesigenic dyskinesia
and other episodic disorders. Eight mutations have been
reported in 249 screened HM cases (Cloarec et al. 2012;
Dale et al. 2012; Gardiner et al. 2012; Marini et al. 2012;
Riant et al. 2012). Both SCN1A and PRRT2 may be
targeted by sequencing in the future, although they are
not expected to explain a substantial proportion of our
unresolved HM cases.
Finally, at least one other FHM locus has been mapped
out of the three known loci, at 14q32, but the underlying
gene still awaits identification (Cuenca-Leon et al. 2009).
It is very likely that most of the unresolved 12 HM
patients from the present cohort and 18 HM patients
from a previous study by our group (Cuenca-Leon et al.
2008) bear mutations in other yet unknown HM genes
that need to be uncovered. Thus, future studies will use
whole-exome sequencing to find new genes responsible
for the disease.
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Supporting Information
Additional Supporting Information may be found in the
online version of this article:
Figure S1. CNV study design using multiplex ligation-
dependent probe amplification (MLPA) and quantitative
multiplex PCR of short fluorescent fragments (QMPSF)
approaches. Symbols (▲) indicate the exons covered by
each assay. The MLPA kit allowed inspection of 24 exons.
The analysis software Coffalyser v8 was used to evaluate
the possible presence of CNVs, considering a deletion
when the ratio was under 0.7 and a duplication when it
was over 1.3. For QMPSF, we used four sets of primer
pairs covering 16 additional exons. A reference fragment
from the RNF20 gene was coamplified in each multiplex.
Furthermore, two individuals with deletions correspond-
ing to exons 20–47 and 32–47 of CACNA1A were also
included in every assay as positive controls. Data were
analyzed using the PeakScannerTM v1.0 software (Applied
Biosystems), and the final ratios for each exon were
expressed using the following formula: (height of the peak
corresponding to the tested fragment for the patient/
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height of the peak corresponding to RNF20 for the
patient)/(height of the peak corresponding to the tested
fragment for the average of controls/height of the peak
corresponding to RNF20 for the average of controls). We
considered a deletion when the ratio was under 0.6 and a
duplication when it was over 1.4.
Data S1. Clinical features of patient #387A and his father.
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